Forge spinoff Blacksmith Medicines merges back into company two years after launch, but details are slim
Blacksmith Medicines and Forge Therapeutics announced Monday that the companies are merging only a year after Blacksmith launched as a spinout of Forge, but there is little information provided on the unification.
The focus will be on infection and oncology research to develop drugs to target metalloenzymes, or enzyme proteins that contain a metal ion like magnesium, zinc, iron, manganese, calcium, cobalt or copper and perform a wide range of functions in the body from mitochondrial function to nitric oxide production. Metalloenzymes account for over 30% of all known enzymes across all species.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.